Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1169-1172

  Noutomi, Takenori ^a   Itoh, Mizue ^a   Toyota, Hiroko ^a   Takada, Eiko ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; c Jun NH2 terminal kinase mitogen activated protein kinases; Carcinoma; Squamous cell; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

LIPOCORTIN 5; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; GENES, DOMINANT; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOUTH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 70449441726     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000551     Document Type: Article

References (33)

1. Scully C and Bagan JV: Recent advances in oral oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 44: 211-215, 2008.
2. Massano J, Regateiro FS, Januario G and Ferreira A: Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 67-76, 2006.
3. Sano D and Myers JN: Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26: 645-662, 2007.
4. Veness MJ, Porceddu S, Palme CE and Morgan GJ: Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 29: 621-631, 2007.
5. Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458, 2006.
6. Eccles SA and Welch DR: Metastasis: recent discoveries and novel treatment strategies. Lancet 369: 1742-1757, 2007.
7. Itoh M, Noutomi T, Toyota H and Mizuguchi J: Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 39: 269-276, 2003.
8. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
9. Oshima K, Yanase N, Ibukiyama C, Yamashina A, Kayagaki N, Yagita H and Mizuguchi J: Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 14: 193-201, 2001.
10. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620, 2000.
11. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
12. Hersey P and Zhang XD: How melanoma cells evade trail-induced apoptosis. Nature Rev Cancer 1: 142-150, 2001.
13. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
14. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M and Mizuguchi J: Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthopaed Res 21: 949-957, 2003.
15. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
16. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044, 2003.
17. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H and Okumura K: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193: 661-670, 2001.
18. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94-100, 2001.
19. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M and Smyth MJ: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 175: 5586-5590, 2005.
20. Noutomi T, Chiba H, Itoh M, Toyota H and Mizuguchi J: Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 38: 41-48, 2002.
21. Takada E, Toyota H, Suzuki J and Mizuguchi J: Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. J Immunol 166: 1641-1649, 2001.
22. Mikami T, Koyama T, Imakiire A, Yamamoto K, Furuhata M, Toyota H and Mizuguchi J: C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Anticancer Res 26: 1153-1160, 2006.
23. Palme CE, Gullane PJ and Gilbert RW: Current treatment options in squamous cell carcinoma of the oral cavity. Surg Oncol Clin N Am 13: 47-70, 2004.
24. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundt AJ and Feldman LE: Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol 43: 213-223, 2007.
25. Gregory MS, Saff RR, Marshak-Rothstein A and Ksander BR: Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand. Cancer Res 67: 11951-11958, 2007.
26. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ and Smyth MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361, 2002.
27. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555-562, 2001.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
29. Vigneswaran N, Wu J, Nagaraj N, Adler-Storthz K and Zacharias W: Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol 26: 103-112, 2005.
30. Cantarella G, Risuglia N, Lombardo G, Lempereur L, Nicoletti F, Memo M and Bernardini R: Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: evidence for multiple sites of interactions. Cell Death Differ 11: 503-511, 2004.
31. Chen YR and Tan TH: The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 16: 651-662, 2000.
32. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000.
33. Lamb JA, Ventura JJ, Hess P, Flavell RA and Davis RJ: JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 11: 1479-1489, 2003.